FDA

In Face of COVID-19, FDA Updates Adverse Event Reporting Guidance Document

By MedTech Intelligence Staff
No Comments
FDA

The goal of the guidance is to ensure that manufacturers are prepared to report adverse events during a pandemic.

FDA recently released guidance for manufacturers of medical devices, drugs, combination products and dietary supplements to explain how the agency plans to enforce adverse event reporting requirements during a pandemic. The guidance document, “Postmarket Adverse Event Reporting for Medical Products and Dietary Supplements During a Pandemic”, intends to help companies that are still responsible for reporting adverse events but also may have limited resources as a result of high employee absenteeism, for example. However, FDA emphasizes that the guidance does not “discourage adverse event reporting during a pandemic by firms that are able to continue reporting operations” nor does it “address monitoring and reporting of adverse events that might be imposed as a condition for medical products authorized for emergency use”.

In addition, the guidance states that industry should have plans in place to ensure the continuity of operations during a pandemic. The guidance outlines the following:

  • Pandemic preparedness
  • Development of a continuity of operations plan in the face of a pandemic
  • FDA’s expectations for adverse event reporting during a pandemic
  • Reporting requirements after a pandemic

Leave a Reply

Your email address will not be published. Required fields are marked *